Trials / Recruiting
RecruitingNCT06885034
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
A Phase 1b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 320 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK5764227 | GSK5764227 will be administered |
Timeline
- Start date
- 2025-06-11
- Primary completion
- 2027-11-11
- Completion
- 2028-06-23
- First posted
- 2025-03-19
- Last updated
- 2025-11-18
Locations
47 sites across 14 countries: United States, Australia, Belgium, Brazil, Canada, France, Italy, Japan, Netherlands, Norway, Poland, South Korea, Spain, Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06885034. Inclusion in this directory is not an endorsement.